Literature DB >> 30421387

Influence of age and subtype in outcome of operable liposarcoma.

Daniela Greto1, Calogero Saieva2, Mauro Loi3, Francesca Terziani3, Luca Visani3, Pietro Garlatti3, Monica Lo Russo3, Cristina Muntoni3, Carlotta Becherini3, Juliana Topulli3, Domenico Campanacci4, Giovanni Beltrami4, Guido Scoccianti4, Francesco Muratori4, Pierluigi Bonomo3, Isacco Desideri3, Giulio Francolini3, Lorenzo Livi3.   

Abstract

AIM: Liposarcoma (LPS) is rare tumor deriving from adipocytes. LPS is classified into histological subtypes: well-differentiated (WDLPS), dedifferentiated (DDLPS), myxoid (MLPS) and pleomorphic (PLPS). A tailored approach taking into account the specificity of disease subtype and age at presentation could be helpful in delineating therapeutic management of liposarcoma. In this paper, we report a retrospective series of a single-institution cohort of patients with LPS, undergoing surgery and radiotherapy and/or chemotherapy. The aim of this study is to evaluate whether clinical characteristics, tumor- and treatment-related features affect clinical outcome in patients treated with curative intent for non-metastatic liposarcoma.
METHODS: Data of patients with locally advanced, non-metastatic liposarcoma treated between 1990 and 2015 were retrospectively reviewed. Data about patient, tumor and treatment features were collected. Two patients subgroups were identified according to age (cutoff: age < 65 years or > 65 years). Statistical analysis was performed to assess correlation between the above-cited variables and local recurrence-free survival (DFS-LR), distant metastasis-free survival, overall survival (OS) and disease-specific survival (DSS); moreover, differences in clinical outcome between the two age groups were identified.
RESULTS: Data of 186 patients were collected. At diagnosis, 27.4% of patients were 65 years or older. At a median follow-up of 8.6 years (range 0.1-27.3 years), Kaplan-Meier (KM) survival analysis showed that LR, DM, OS and DSS were 75.5%, 76.6%, 48.1% and 72.1%, respectively. KM analysis showed that age > 65, DDLPS and lower limb localization were related to LR (p = 0.001, p = 0.0001 and p = 0.0001, respectively). Association between LR, age and DDLPS persisted both at univariate (p = 0.003 and p = 0.0001, respectively) and multivariate Cox regression (CR) analysis (p = 0.024 and p = 0.002). Age, tumor depth and grading influenced distant recurrence, both at KM (p = 0.023, p = 0.026 and p = 0.016) and univariate CR (p = 0.026, p = 0.042 and p = 0.012). Age and grading were confirmed at multivariate analysis (p = 0.009 and p = 0.017). Patients with WDLPS and wide excision had significantly better OS (p = 0.001 and p = 0.03, respectively), while histological G3 and age > 65 were related with worse OS (p = 0.008 and p = 0.0001, respectively). Age, DDLPS and grade were related to OS at univariate (p = 0.0001, p = 0.0001 and p = 0.03, respectively) and multivariate CR analysis (p = 0.031, p = 0.0001 and p = 0.001, respectively). However, analyzing the specific causes of death, female died less often for tumor-related causes, with a DSS of 91.0% compared to 57.4% of male counterpart (p = 0.005). At Kaplan-Meier analysis, postoperative radiotherapy resulted in a statistically significant better disease-specific survival than postoperative radiotherapy (82.9% vs. 46.2%, p = 0.045). High grade correlated with poorer disease-specific survival (59.3%) than intermediate and low grade (73.4% and 91.6%, respectively) (p = 0.008). Association between DSS, sex and grade persisted both at univariate (p = 0.008 and p = 0.022, respectively) and multivariate Cox regression (CR) analysis (p = 0.014 and p = 0.038). Histotype-driven schedules of treatment should be developed to take into account biological heterogeneity of this disease. Further studies are needed to stratify patients subgroup and develop tailored treatment strategies (i.e., altered fractionations and different chemotherapy regimens in aggressive subtypes), in particular more prospective trials are needed to develop treatment guidelines in elderly STS, taking into account the frailty and the peculiarity of this subgroup.

Entities:  

Keywords:  Age; Liposarcoma; Radiotherapy; Soft tissue sarcoma

Mesh:

Substances:

Year:  2018        PMID: 30421387     DOI: 10.1007/s11547-018-0958-4

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  34 in total

1.  Adverse effect of older age on the recurrence of soft tissue sarcoma of the extremities and trunk.

Authors:  David J Biau; Peter C Ferguson; Robert E Turcotte; Peter Chung; Marc H Isler; Soha Riad; Anthony M Griffin; Charles N Catton; Brian O'Sullivan; Jay S Wunder
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

2.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

Authors:  J D Cox; J Stetz; T F Pajak
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

3.  Metastasis in dedifferentiated liposarcoma: Predictors and outcome in 148 patients.

Authors:  S H Tirumani; H Tirumani; J P Jagannathan; A B Shinagare; J L Hornick; N H Ramaiya; A J Wagner
Journal:  Eur J Surg Oncol       Date:  2015-01-24       Impact factor: 4.424

4.  The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.

Authors:  Fritz C Eilber; Frederick R Eilber; Jeffery Eckardt; Gerald Rosen; Elyn Riedel; Robert G Maki; Murray F Brennan; Samuel Singer
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

5.  Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial.

Authors:  Brian O'Sullivan; Aileen M Davis; Robert Turcotte; Robert Bell; Charles Catton; Pierre Chabot; Jay Wunder; Rita Kandel; Karen Goddard; Anna Sadura; Joseph Pater; Benny Zee
Journal:  Lancet       Date:  2002-06-29       Impact factor: 79.321

6.  Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas.

Authors:  Peter W M Chung; Benjamin M Deheshi; Peter C Ferguson; Jay S Wunder; Anthony M Griffin; Charles N Catton; Robert S Bell; Lawrence M White; Rita A Kandel; Brian O'Sullivan
Journal:  Cancer       Date:  2009-07-15       Impact factor: 6.860

Review 7.  Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies.

Authors:  Khin Thway; Robin L Jones; Jonathan Noujaim; Shane Zaidi; Aisha B Miah; Cyril Fisher
Journal:  Adv Anat Pathol       Date:  2016-01       Impact factor: 3.875

8.  Neoadjuvant treatment of soft tissue sarcoma.

Authors:  Daniela Greto; Lorenzo Livi; Calogero Saieva; Pierluigi Bonomo; Icro Meattini; Mauro Loi; Lucia Di Brina; Giovanni Beltrami; Domenico Campanacci; Guido Scoccianti; Rodolfo Capanna; Monica Mangoni; Fabiola Paiar; Alessandro Franchi; Giampaolo Biti
Journal:  Radiol Med       Date:  2013-11-26       Impact factor: 3.469

9.  Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

Authors:  P A Cassier; V Polivka; I Judson; J-C Soria; N Penel; S Marsoni; J Verweij; J H Schellens; R Morales-Barrera; P Schöffski; E E Voest; C Gomez-Roca; T R J Evans; R Plummer; E Gallerani; S B Kaye; D Olmos
Journal:  Ann Oncol       Date:  2014-03-07       Impact factor: 32.976

10.  Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy.

Authors:  Hyo Song Kim; Jeeyun Lee; Seong Yoon Yi; Hyun Jung Jun; Yoon-La Choi; Geung Hwan Ahn; Sung Wook Seo; Do Hoon Lim; Yong Chan Ahn; Joon Oh Park; Sung Joo Kim
Journal:  BMC Cancer       Date:  2009-06-26       Impact factor: 4.430

View more
  8 in total

1.  Prognostic Significance of Histological Subtype in Soft Tissue Sarcoma With Distant Metastasis.

Authors:  Hiroyuki Tsuchie; Makoto Emori; Naohisa Miyakoshi; Hiroyuki Nagasawa; Kyoji Okada; Yasutaka Murahashi; Emi Mizushima; Junya Shimizu; Toshihiko Yamashita; Yoichi Shimada
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 2.  INTERACTS (INTErventional Radiotherapy ACtive Teaching School) consensus conference on sarcoma interventional radiotherapy (brachytherapy) endorsed by AIRO (Italian Association of Radiotherapy and Clinical Oncology).

Authors:  Luca Tagliaferri; Andrea Vavassori; Valentina Lancellotta; Vitaliana De Sanctis; Cristiana Vidali; Calogero Casà; Cynthia Aristei; Domenico Genovesi; Barbara Alicja Jereczek-Fossa; Alessio Giuseppe Morganti; György Kovács; Jose Luis Guinot; Agata Rembielak; Daniela Greto; Maria Antonietta Gambacorta; Vincenzo Valentini; Vittorio Donato; Renzo Corvò; Stefano Maria Magrini; Lorenzo Livi
Journal:  J Contemp Brachytherapy       Date:  2020-08-21

3.  Increasing Incidence of Liposarcoma: A Population-Based Study of National Surveillance Databases, 2001-2016.

Authors:  Suzanne Bock; Douglas G Hoffmann; Yi Jiang; Hao Chen; Dora Il'yasova
Journal:  Int J Environ Res Public Health       Date:  2020-04-15       Impact factor: 3.390

4.  Survival analysis and treatment strategies for limb liposarcoma patients with metastasis at presentation.

Authors:  Shicheng Wang; Yuanxi Zhou; Haifeng Wang; Jing Ling
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

5.  The Role of Radiotherapy in Soft Tissue Sarcoma on Extremities With Lymph Nodes Metastasis: An IPTW Propensity Score Analysis of the SEER Database.

Authors:  Xinzhu Qiu; Hongbo He; Hao Zeng; Xiaopeng Tong; Qing Liu
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

6.  Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.

Authors:  Paul Rogowski; Christian Trapp; Rieke von Bestenbostel; Chukwuka Eze; Ute Ganswindt; Minglun Li; Marcus Unterrainer; Mathias J Zacherl; Harun Ilhan; Leonie Beyer; Alexander Kretschmer; Peter Bartenstein; Christian Stief; Claus Belka; Nina-Sophie Schmidt-Hegemann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-10       Impact factor: 9.236

7.  Evaluation of Efficacy of Adjuvant Radiotherapy in Well-Differentiated Liposarcoma Patients with Positive Surgical Margins: A Population-based Study.

Authors:  Haoran Wang; Boran Chen; Ying Cen; Junjie Chen
Journal:  J Oncol       Date:  2022-09-08       Impact factor: 4.501

Review 8.  Management of myxoid liposarcoma of the extremity.

Authors:  Yehia Tfayli; Ahmad Baydoun; Ahmad Salaheddine Naja; Said Saghieh
Journal:  Oncol Lett       Date:  2021-06-09       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.